This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cramer's 'Mad Money' Recap: Bubble? What Bubble?

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Has the market become ridiculously overvalued? Jim Cramer tackled the bear argument that the markets have entered bubble territory on his "Mad Money" TV show Thursday.

He said the bears are right... partially.

When looking at the markets overall, the S&P 500 only trades at 15 times earnings. That's the index's historical average -- no bubble there, Cramer said. Likewise with the Dow Jones Industrial Average, which trades at 14 times earnings, also near its historical norms. There's also no bubble when it comes to stocks versus bonds, noted Cramer, as bonds still pay next to nothing while stock dividends continue to enjoy favorable tax treatment.

So where are these bubbles the bears keep citing on TV? Cramer said he's worried about the utility stocks, for one, as that sector is now at 4.5 year highs, a level that's simply not sustainable once the Federal Reserve slows or stops its bond buying.

Then there are other groups that have have miraculous runs, mainly the food and beverage names and the drug stocks. Cramer said he sold Bristol-Myers Squibb (BMY) for his charitable trust, Action Alerts PLUS, as that stock now trades at 2.5 times its grow rate and leaves little room for error when the company reports later this month.

The upside in these sectors is limited, said Cramer, because the stock prices have run and their yields have fallen, making them less attractive overall. So while there may not be a bubble in the markets as a whole, these are some of the areas investors need to be cautious about.

Sell Block: Teva

In the Thursday "Sell Block" segment, Cramer focused on a drug stock investors should avoid: Teva Pharmaceuticals (TEVA), the world's largest generic drug maker.

Cramer said the generic drug business was a thing of beauty back in the 1990s and 2000s as companies like Teva took the process of formulating generic versions of branded drugs to an art form, sometimes offering them just months after their branded counterparts lost their patent protection. But that golden age is no more, said Cramer, because there are fewer blockbuster drugs coming off patent and competition to make the generics has increased.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,003.34 +20.75 0.12%
S&P 500 1,979.68 +0.77 0.04%
NASDAQ 4,458.2340 +13.3250 0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs